US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

IPN

Ipsen (IPN)

Ipsen SA

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:EU:IPN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/07	21 : 55	GlobeNewswire Inc.	IPSEN SA. - Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée Générale Mixte du 28 mai 2024	EU:IPN	Ipsen SA
2024/05/07	21 : 55	GlobeNewswire Inc.	Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting	EU:IPN	Ipsen SA
2024/05/07	01 : 00	GlobeNewswire Inc.	Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	EU:IPN	Ipsen SA
2024/05/07	01 : 00	GlobeNewswire Inc.	Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital	EU:IPN	Ipsen SA
2024/05/02	14 : 30	GlobeNewswire Inc.	Ipsen appoints Keira Driansky as EVP, President of North America	EU:IPN	Ipsen SA
2024/05/02	14 : 30	GlobeNewswire Inc.	Ipsen appoints Keira Driansky as EVP, President of North America	EU:IPN	Ipsen SA
2024/05/02	14 : 30	GlobeNewswire Inc.	Ipsen nomme Keira Driansky, en qualité de Vice-Présidente Exécutive, et Présidente Amérique du Nord	EU:IPN	Ipsen SA
2024/04/24	14 : 00	GlobeNewswire Inc.	Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance	EU:IPN	Ipsen SA
2024/04/24	14 : 00	GlobeNewswire Inc.	Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance	EU:IPN	Ipsen SA
2024/04/24	14 : 00	GlobeNewswire Inc.	Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024	EU:IPN	Ipsen SA
2024/04/22	14 : 00	GlobeNewswire Inc.	Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases	EU:IPN	Ipsen SA
2024/04/22	14 : 00	GlobeNewswire Inc.	Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases	EU:IPN	Ipsen SA
2024/04/22	14 : 00	GlobeNewswire Inc.	Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares	EU:IPN	Ipsen SA
2024/04/18	01 : 00	GlobeNewswire Inc.	Ipsen publishes its 2023 Universal Registration Document	EU:IPN	Ipsen SA
2024/04/18	01 : 00	GlobeNewswire Inc.	Ipsen publie son Document d’enregistrement universel 2023	EU:IPN	Ipsen SA
2024/04/09	01 : 00	GlobeNewswire Inc.	Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	EU:IPN	Ipsen SA
2024/04/09	01 : 00	GlobeNewswire Inc.	Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital	EU:IPN	Ipsen SA
2024/04/02	14 : 00	GlobeNewswire Inc.	Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides	EU:IPN	Ipsen SA
2024/04/02	14 : 00	GlobeNewswire Inc.	Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors	EU:IPN	Ipsen SA
2024/04/02	14 : 00	GlobeNewswire Inc.	Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors	EU:IPN	Ipsen SA
2024/03/08	02 : 00	GlobeNewswire Inc.	Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital	EU:IPN	Ipsen SA
2024/03/08	02 : 00	GlobeNewswire Inc.	Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	EU:IPN	Ipsen SA
2024/02/15	18 : 00	GlobeNewswire Inc.	Ipsen S.A. publie ses comptes consolidés 2023	EU:IPN	Ipsen SA
2024/02/15	18 : 00	GlobeNewswire Inc.	Ipsen S.A. publishes its 2023 Consolidated Financial Statements	EU:IPN	Ipsen SA
2024/02/14	06 : 08	GlobeNewswire Inc.	Ipsen reçoit l’approbation de la FDA pour le schéma thérapeutique incluant Onivyde®, un potentiel nouveau traitement de référence en première ligne dans l'adénocarcinome du pancréas métastatique	EU:IPN	Ipsen SA
2024/02/14	06 : 08	GlobeNewswire Inc.	Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA	EU:IPN	Ipsen SA
2024/02/14	06 : 08	GlobeNewswire Inc.	Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA	EU:IPN	Ipsen SA
2024/02/08	14 : 58	GlobeNewswire Inc.	Building on solid FY 2023 results, Ipsen anticipates four launches in 2024	EU:IPN	Ipsen SA
2024/02/08	14 : 58	GlobeNewswire Inc.	Après de solides résultats pour l’année 2023, Ipsen anticipe quatre lancements commerciaux en 2024.	EU:IPN	Ipsen SA
2024/02/08	14 : 58	GlobeNewswire Inc.	Building on solid FY 2023 results, Ipsen anticipates four launches in 2024	EU:IPN	Ipsen SA

Showing the most relevant articles for your search:EU:IPN

1 2 3 4 5 6 7 8 9 10 次へ >>

Financial Select Sector

JP Morgan Chase

BNP Paribas (QX)

Verizon Communications

US Dollar vs Euro

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約